Discussion
Most adults with late-onset Pompe disease (LOPD) interviewed after participating in clinical studies of Pombiliti plus Opfolda (cipaglucosidase alfa/miglustat) found the treatment manageable, and more than half reported improvements in their quality of life, a small interview study shows. Participants also generally felt well informed about the studies…